LINKÖPING, Sweden, March 12, 2025 –We’re pleased to share that AMRA Medical—led by Markus Karlsson, PhD, and colleagues from Linköping and Lund Universities—will present recent findings on chronic kidney disease (CKD) and muscle composition at the 15th International Conference on Frailty & Sarcopenia Research (ICFSR) 2025 in lovely Toulouse, France, from March 12th-14th!
Recent findings from the study titled “Adverse muscle composition in chronic kidney disease predicts all-cause mortality in the UK Biobank Imaging Study”, show that adverse muscle composition (AMC)—defined by low muscle volume z-score and high muscle fat infiltration—strongly predicts all-cause mortality in chronic kidney disease (CKD).
Using MRI data from nearly 900 UK Biobank participants with CKD, the study showed 32.3% of the participants had AMC and faced a markedly higher mortality risk over four years (HR[1] [2] 6.17). After adjusting for factors such as age, sex, BMI, and grip strength, AMC remained a robust predictor (HR 4.21). These results underscore the value of MRI-based muscle composition assessments to support clinical trials evaluating risk and interventions in CKD.
Participants exhibiting poor muscle health may benefit from targeted interventions—ranging from nutritional support to physical exercise — potentially improving outcomes and survival. AMC assessment could also help identify a high-risk subgroup within CKD populations to target in clinical trials evaluating emerging treatments.
You can watch AMRA’s Jennifer Linge, PhD share the study findings live during the “Oral Communications” session of ICFSR 2025 on Thursday, March 13th, beginning at 10:40 CET.
AMRA remains committed to advancing precision imaging biomarkers that uncover the role of muscle health in kidney disease trials and beyond. If you want to catch us at ICFSR 2025, feel free to connect with us via info@amramedical.com! We look forward to seeing you there!
About AMRA Medical
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA’s gold-standard technology delivers multiple fat and muscle biomarkers – derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform.
Follow AMRA on LinkedIn for the latest updates in fat distribution and muscle composition assessments in disease research.
MEDIA CONTACT INFORMATION
AMRA Medical
Marie Börjesson, VP Brand & Marketing
0046 70 628 1977
marie.borjesson@amramedical.com